Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

VITALITY DX LLC

NPI: 1386246858 · LEXINGTON, KY 40505 · Clinical Medical Laboratory · NPI assigned 11/10/2020

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official FISHER, TAMIA controls 13+ related entities in our dataset. Read more

$2.05M
Total Medicaid Paid
41,403
Total Claims
21,310
Beneficiaries
32
Codes Billed
2020-11
First Month
2023-05
Last Month

Provider Details

Authorized OfficialFISHER, TAMIA (CREDENTIALING)
NPI Enumeration Date11/10/2020

Related Entities

Other providers sharing the same authorized official: FISHER, TAMIA

ProviderCityStateTotal Paid
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC LEXINGTON KY $6.25M
COMMONWEALTH PAIN SPECIALISTS, PLLC FRANKFORT KY $2.14M
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC LEXINGTON KY $1.22M
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC EVANSVILLE IN $522K
INTERVENTIONAL PAIN & SPINE SPECIALISTS, LLC LOUISVILLE KY $462K
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC BOWLING GREEN KY $374K
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC LOUISVILLE KY $323K
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC BOWLING GREEN KY $308K
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC FRANKFORT KY $177K
INTERVENTIONAL PAIN & SPINE SPECIALISTS LLC LOUISVILLE KY $136K
VITALITY PAIN MANAGEMENT LLC BOWLING GREEN KY $116K
X-GENE MOLECULAR LABORATORIES, INC LOUISVILLE KY $50K
KINGDOM COUNSELING CHANDLER IN $7K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 3,480 $86K
2021 28,638 $1.41M
2022 8,066 $441K
2023 1,219 $120K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 14,710 4,689 $1.04M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 8,125 3,284 $426K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 3,195 1,952 $226K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 4,443 2,670 $172K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,405 1,175 $66K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 875 692 $20K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1,999 1,138 $20K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 596 561 $15K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 1,927 1,205 $15K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1,062 1,029 $13K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 1,060 1,027 $13K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1,060 1,027 $13K
87631 63 57 $3K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 15 15 $3K
86413 194 178 $3K
86409 179 179 $2K
87640 74 61 $266.76
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 23 16 $227.50
81025 22 22 $73.74
85025 Blood count; complete (CBC), automated, and automated differential WBC count 72 61 $10.56
86022 31 28 $8.96
83036 Hemoglobin; glycosylated (A1C) 19 17 $0.00
84443 Thyroid stimulating hormone (TSH) 25 22 $0.00
85018 30 28 $0.00
80053 Comprehensive metabolic panel 40 34 $0.00
85027 32 28 $0.00
80048 Basic metabolic panel (calcium, ionized) 17 13 $0.00
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 19 17 $0.00
85014 30 28 $0.00
85049 30 28 $0.00
85041 15 15 $0.00
80061 Lipid panel 16 14 $0.00